These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The use of cyclosporine in living-related renal transplantation. Donor-specific hyporesponsiveness and steroid withdrawal.
    Author: Flechner SM, Kerman RH, Van Buren CT, Epps L, Kahan BD.
    Journal: Transplantation; 1984 Dec; 38(6):685-91. PubMed ID: 6239415.
    Abstract:
    Fourteen HLA-identical (HLA-ID) and 62 haploidentical (HP-ID) living-related donor (LRD) renal allograft recipients were transplanted using cyclosporine (CsA) and prednisone immunosuppression. No patients were preconditioned with pretransplant blood transfusions (third-party or donor-specific)--and, therefore, none were sensitized to their donor. Patient 93% (13/14) and graft 93% (13/14) survival for the HLA-ID patients is not significantly different (P greater than .1) compared with patient 98% (61/62) and graft 91% (56/62) survival in the HP-ID patients, with a mean follow-up of 16.3 (8-30) and 14.7 (2-35) months, respectively. A significant difference was noted in the incidence of treated rejection episodes (0% vs. 31%, P less than .01) and the mean serum (mg/dl) creatinine (1.37 vs. 1.71, P less than .05) at 18 months between the HLA-ID and the HP-ID and HP-ID recipients, respectively. Ten of 22 HP-ID recipients demonstrated donor-specific mixed lymphocyte culture hyporesponsiveness one year posttransplant that may have been due to the emergence of monocytoid suppressor cells. Nine of these HP-ID and seven HLA-ID recipients were subjected to a protocol of steroid withdrawal. Eleven of these patients are currently on CsA monodrug therapy and two are on alternate-day steroids from 9-18 months after discontinuation of prednisone. These findings suggest that CsA is an effective steroid-sparing agent in LRD renal transplantation that diminishes the frequency of treated rejection episodes and may permit monodrug therapy in selected individuals.
    [Abstract] [Full Text] [Related] [New Search]